The Most Expensive Part of mIHC is Actually Not the Reagents

Many people, when first encountering multiplex immunofluorescence (mIHC / TSA multiplex IF), instinctively equate cost with "how much the kit costs". But those who have actually done the experiments know that this judgment is only half correct, or even, only captures the least important half.

Let us concretize the failure process of a typical mIHC panel. Suppose we are constructing a 5-6 marker tumor immune microenvironment panel. The first experiment failure may manifest as excessive background signal, quenching instability in a certain fluorescence channel, or interference between antibody sequences leading to signal overlay errors. Intuitively, it seems that only further condition adjustment is needed to retry. But the real cost is often systematic: an extremely precious FFPE tissue section has already been consumed in the process, a set of antibodies that have been screened and labeled is wasted as a whole, and a complete experimental cycle (usually requiring 3 to 7 days or longer) is completely reset. Subsequent microscope scanning and image analysis work must also start all over again. More importantly, the spatial structure information of the sample may have already suffered irreversible loss during this process. Once repeated experiments begin, the original spatial state can no longer be completely reproduced. If the same problem is placed in traditional IHC or single-marker IF systems, this loss will be further amplified, because each marker must rely on a separate section for staining, causing the failure cost to increase exponentially at the sample level.

If we break down an mIHC experiment, its cost actually consists of four parts, and the latter two are often severely underestimated:

• First is the reagent cost, including primary antibodies, secondary antibody systems, TSA fluorescent dyes, anti-fade mounting media, etc. This is the "visible cost" and the price item most easily compared.
• Second is the consumable cost, including slides, sectioning blades, antigen retrieval buffers, blocking solutions, etc. This may seem low per use, but it is continuously consumed during multiple rounds of optimization.
• What really begins to widen the gap is the third part: tissue section cost. Especially for tumor samples, precious human samples, or key tissues from animal models, one section is often non-renewable and even irreplaceable. The bottleneck for many projects is not whether they can get results, but whether they still have samples to continue testing.
• Finally, and most implicitly: labor time. A standard mIHC panel, from optimization to stabilization, often requires multiple rounds of antibody screening, concentration gradients, sequence optimization, and signal balance adjustment. Each repetition consumes days to weeks of time.

Traditional IHC or single-marker IF often appears cheaper in terms of intuitive cost, so it is easily preferred in the early stages of experimental design. However, if we disassemble from the structural perspective of the experimental system, we will find that it inherently contains a long-overlooked problem: it must rely on multiple sections stained separately to obtain multi-indicator information. This design path means that the same tissue region must be cut into multiple serial sections, and each section must complete antigen retrieval, blocking, antibody incubation, and visualization as an independent experimental system. The final data integration can only rely on "image stitching inference" between different sections.

The problem is that this cross-section analysis logic itself has an unavoidable structural flaw: natural spatial offset exists between tissue sections. Even with very mature sectioning techniques, it is impossible to ensure complete spatial alignment at the cellular level for serial sections. This tiny but uncontrollable deviation will be continuously amplified in high-resolution spatial analysis. Thus, a very practical problem arises: you think you are doing "multi-marker co-localization", but in reality, you are doing "cross-section approximate comparison".

In contrast, the core advantage of the TSA-mIHC system lies precisely in fundamentally changing this information acquisition logic. Through the tyramide signal amplification system enabling multiple rounds of cyclic staining, it can sequentially detect multiple biomarkers on the same section, achieving true "multi-indicator co-localization at the same spatial coordinates". In this system, researchers can directly observe whether the same T cell expresses both PD-1 and TIM-3; can clearly see whether CD68+ macrophages truly spatially enrich around the same tumor nest; and can more accurately determine whether immune checkpoints show synergistic expression or mutually exclusive distribution within the same microenvironment structure.

In actual scientific research, people often focus on reagent costs, but once they enter the experimental system, they will find that antibody prices are not the most critical limiting factor. What is truly scarce and irreplaceable is actually the samples themselves. Whether it is clinical tumor FFPE samples, rare subtype patient tissues with limited sources, key tissues at specific time points in animal models, or limited section resource libraries accumulated over a long period in the laboratory, these materials cannot be regenerated once consumed, so their value is much higher than conventional reagents. In this context, if inefficient or unstable experimental protocols are used, it directly leads to sample waste, and this loss is irreversible. Especially in the multi-section system of traditional IHC or single-marker IF, the same tissue often needs to be cut into multiple serial sections for separate staining experiments. This not only increases experimental complexity but also splits the sample into multiple independent experimental units. Once any section fails staining, it means the entire spatial information structure cannot be completely restored. In contrast, one of the core advantages of mIHC technology is its ability to complete multi-indicator co-staining on a single section, thereby maximizing the spatial information density in limited samples and avoiding structural information loss caused by multi-section strategies.

On the surface, mIHC kits and technical services are usually more expensive than ordinary reagent combinations, so many people intuitively think their costs are higher. However, if measured from the full-cycle cost of the entire experimental system, this option is often actually the more economical choice. The reason is that mature kit systems not only provide reagents themselves, but also include validated antibody screening strategies, optimized staining sequence designs, stable antigen retrieval conditions, and signal balance protocols. These implicit technical paths can significantly reduce the large amount of time costs spent by researchers in the early exploration stage. At the same time, standardized protocols can effectively reduce the number of repeated experiments and improve the success rate of the first experiment, thereby reducing reagents, samples, and instrument time consumed due to repeated optimization. In other words, what is being purchased is not simply "chemical reagents", but an engineered and validated "success probability improvement system". When an mIHC panel changes from requiring three or more rounds of failed optimization to stabilize, to achieving reliable results in one or two attempts, what is saved is not just reagent costs, but the most expensive resources in the entire experimental chain — the comprehensive consumption of time and samples.